1MRNA Stock Overview
A biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Moderna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.12 |
| 52 Week High | US$157.28 |
| 52 Week Low | US$34.23 |
| Beta | 1.69 |
| 11 Month Change | -19.29% |
| 3 Month Change | -45.35% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -69.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1MRNA | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | 15.3% | 2.9% | -1.6% |
| 1Y | n/a | 5.3% | 12.4% |
Return vs Industry: Insufficient data to determine how 1MRNA performed against the Italian Biotechs industry.
Return vs Market: Insufficient data to determine how 1MRNA performed against the Italian Market.
Price Volatility
| 1MRNA volatility | |
|---|---|
| 1MRNA Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IT Market | 7.5% |
| 10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: 1MRNA's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: 1MRNA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5,600 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
| 1MRNA fundamental statistics | |
|---|---|
| Market cap | €15.19b |
| Earnings (TTM) | -€2.14b |
| Revenue (TTM) | €4.88b |
3.1x
P/S Ratio-7.1x
P/E RatioIs 1MRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1MRNA income statement (TTM) | |
|---|---|
| Revenue | US$5.08b |
| Cost of Revenue | US$6.48b |
| Gross Profit | -US$1.40b |
| Other Expenses | US$824.00m |
| Earnings | -US$2.22b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.78 |
| Gross Margin | -27.55% |
| Net Profit Margin | -43.77% |
| Debt/Equity Ratio | 0% |
How did 1MRNA perform over the long term?
See historical performance and comparison